-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, the study was designed to evaluate the sodium - glucose cotransporter 2 inhibitors in reducing type 2 diabetes efficacy rates of adult mortality and cardiovascular outcomes occur
.
The researchers conducted a Bayesian meta-analysis of randomized controlled trials comparing sodium-glucose cotransporter 2 inhibitors with placebo, and used meta-regression to assess the association between treatment effects and the incidence of events in the control group
.
53 randomized controlled trials were included in the synthetic analysis
.
Enpagliflozin, canagliflozin and dapagliflozin reduced all-cause mortality (empagliflozin: ratio [RR] of 0.
79; 95% confidence interval [CI] of 0.
63-0.
97; canagliflozin Net: RR is 0.
86; 95%CI is 0.
There is little evidence that Ieggliflozin and Soxaggliflozin can reduce all-cause mortality and cardiovascular mortality compared with placebo
.
There was no correlation between the treatment effect of all-cause mortality and cardiovascular mortality and the incidence of events in the control group
Compared with placebo in stroke , empagliflozin, canagliflozin and dapagliflozin reduced the incidence of all-cause mortality and cardiovascular mortality
Original source:
Matthew S.
Freiberg.
et al.
HIV Infection and the Risk of World Health Organization--Defined Sudden Cardiac Death .
JAHA.